U.S. Industrial REITs Stock News

NYSE:FERG
NYSE:FERGTrade Distributors

Assessing Ferguson Enterprises (FERG) Valuation After Recent Share Price Weakness

Recent performance snapshot Ferguson Enterprises (FERG) has attracted fresh attention after recent share price pressure, with the stock down 2.1% on the day, 7.5% over the past week and about 6.0% over the past month. Over the past 3 months, the share price is down roughly 8.5%, while longer term total returns, including dividends, are 7.3% year to date, 38.8% over the past year, 72.2% over 3 years and 103.9% over 5 years. See our latest analysis for Ferguson Enterprises. Recent weakness,...
NYSE:ACA
NYSE:ACAConstruction

Why Arcosa (ACA) Is Up 5.5% After Raising 2026 Revenue Guidance And Buying Back Shares

In April 2026, Arcosa, Inc. reported first-quarter sales of US$571.7 million and net income of US$37.8 million, while also updating its full-year 2026 consolidated revenue guidance to a range of US$2.6 billion to US$2.7 billion, above its prior outlook. Alongside stronger earnings, Arcosa completed a US$17.23 million share repurchase of 159,595 shares, subtly reinforcing management’s confidence in the company’s longer-term prospects. We’ll now examine how Arcosa’s raised 2026 revenue...
NYSE:UE
NYSE:UERetail REITs

Urban Edge Properties (UE) Valuation Check After Strong Earnings Beat And Higher 2026 Guidance

Urban Edge Properties (UE) recently paired stronger first quarter earnings with higher full year 2026 earnings guidance, giving investors fresh information on both current performance and management expectations for the rest of the year. See our latest analysis for Urban Edge Properties. The recent earnings beat and higher 2026 guidance come alongside a 13.14% year to date share price return and a 17.72% total shareholder return over the past year, suggesting momentum has built over time...
NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

Why PTC Therapeutics (PTCT) Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance

In early May 2026, PTC Therapeutics reported first-quarter revenue of US$272.55 million versus US$1.18 billion a year earlier, swinging from net income of US$866.56 million to a net loss of US$2.81 million while still beating analyst expectations on both revenue and earnings per share. The company also released positive 24-month interim data for Huntington’s disease therapy votoplam and raised its 2026 product revenue guidance, underscoring how a strong Sephience launch and advancing...
NYSE:SBSI
NYSE:SBSIBanks

A Look At Southside Bancshares (SBSI) Valuation After Q1 Earnings Growth And Dividend Reaffirmation

Southside Bancshares (SBSI) drew fresh attention after reporting first quarter 2026 results and affirming a quarterly dividend of $0.36 per share, pairing earnings information with a continued cash return to shareholders. See our latest analysis for Southside Bancshares. The recent first quarter update and confirmed dividend come after a steadily improving share price. The 1 month share price return was 5.12% and the year to date share price return was 10.51%, alongside a 1 year total...